SCPH scPharmaceuticals Inc
Price (delayed)
$2.5
Market cap
$125.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.91
Enterprise value
$129.62M
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships,
Highlights
The revenue has surged by 167% year-on-year and by 20% since the previous quarter
scPharmaceuticals's gross profit has surged by 155% YoY and by 18% QoQ
SCPH's debt has soared by 98% YoY
The equity has plunged by 64% YoY and by 57% from the previous quarter
Key stats
What are the main financial stats of SCPH
Market
Valuations
Earnings
Shares outstanding
50.28M
Market cap
$125.71M
Enterprise value
$129.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
9.39
Price to sales (P/S)
3.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.57
Revenue
$36.33M
Gross profit
$24.97M
Operating income
-$64.78M
Net income
-$85.15M
EBIT
-$77.58M
EBITDA
-$77.43M
Free cash flow
-$70.56M
Per share
Balance sheet
Liquidity
EPS
-$1.91
EPS diluted
-$1.91
Free cash flow per share
-$1.58
Book value per share
$0.27
Revenue per share
$0.82
TBVPS
$2.42
Total assets
$107.52M
Total liabilities
$94.2M
Debt
$79.56M
Equity
$13.32M
Working capital
$90.97M
Debt to equity
5.97
Current ratio
7.12
Quick ratio
5.87
Net debt/EBITDA
-0.05
Margins
Efficiency
Dividend
EBITDA margin
-213.1%
Gross margin
68.7%
Net margin
-234.4%
Operating margin
-178.3%
Return on assets
-90.5%
Return on equity
-437.5%
Return on invested capital
-104.1%
Return on capital employed
-83.7%
Return on sales
-213.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SCPH stock price
How has the scPharmaceuticals stock price performed over time
Intraday
7.3%
1 week
-16.94%
1 month
-23.78%
1 year
-47.7%
YTD
-29.38%
QTD
-4.94%
Financial performance
How have scPharmaceuticals's revenue and profit performed over time
Revenue
$36.33M
Gross profit
$24.97M
Operating income
-$64.78M
Net income
-$85.15M
Gross margin
68.7%
Net margin
-234.4%
The revenue has surged by 167% year-on-year and by 20% since the previous quarter
scPharmaceuticals's gross profit has surged by 155% YoY and by 18% QoQ
scPharmaceuticals's operating margin has soared by 56% YoY and by 15% from the previous quarter
scPharmaceuticals's net income has shrunk by 55% YoY and by 6% QoQ
Growth
What is scPharmaceuticals's growth rate over time
Valuation
What is scPharmaceuticals stock price valuation
P/E
N/A
P/B
9.39
P/S
3.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.57
The company's EPS fell by 35% YoY
The price to book (P/B) is 72% more than the 5-year quarterly average of 5.1 but 23% less than the last 4 quarters average of 11.3
The equity has plunged by 64% YoY and by 57% from the previous quarter
The revenue has surged by 167% year-on-year and by 20% since the previous quarter
SCPH's price to sales (P/S) is 61% lower than its last 4 quarters average of 7.4
Efficiency
How efficient is scPharmaceuticals business performance
scPharmaceuticals's return on invested capital has shrunk by 84% YoY
The return on assets has dropped by 82% year-on-year and by 2.6% since the previous quarter
SCPH's ROE is down by 39% since the previous quarter
The company's return on sales rose by 38% YoY and by 10% QoQ
Dividends
What is SCPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SCPH.
Financial health
How did scPharmaceuticals financials performed over time
The company's total assets is 14% higher than its total liabilities
scPharmaceuticals's total liabilities has soared by 65% YoY
The company's total assets fell by 14% QoQ but it rose by 14% YoY
SCPH's debt to equity has surged by 131% since the previous quarter
SCPH's debt has soared by 98% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.